Celltrion's Zymfentra Beats IV Infliximab in Ileal Crohn's Data
Jersey City – October 11, 2026 -- Subcutaneous (SC) infliximab delivered clinical remission in 71.4% of matched patients with ileum-dominant Crohn's disease at Week 54, against 51.4% for intravenous (IV) infliximab, according to a late-breaking analysis Celltrion USA will present for ZYMFENTRA (infliximab-dyyb) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee.
Matched analysis shows wider endoscopic gap for SC infliximab at Week 54
The pooled analysis used individual patient data from four infliximab registrational studies. Of 884 patients, 200 with ileal or ileocolonic Crohn's disease met eligibility criteria. They received either SC infliximab 120 mg every two weeks or IV infliximab 5 mg/kg every eight weeks. A 1:1 propensity score-matched analysis included 70 patients per arm.
SC infliximab outperformed IV infliximab on all three measures in the matched population: